LSA
OVID icon

Leonteq Securities AG’s Ovid Therapeutics OVID Stock Holding History

Leonteq Securities AG’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,000
Closed -$27.7K – 1070
2020
Q4 		$27.7K Buy
+12,000
New +$55.9K ﹤0.01% 865

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Leonteq Securities AG's OVID Position: Q1 2021 in Review

Leonteq Securities AG sold out of Ovid Therapeutics (OVID) in Q1 2021, closing a stake of 12,000 shares — an estimated $27.7K sold.

Leonteq Securities AG first reported a position in OVID in Q4 2020 and held it in 1 quarter. The position peaked at $27.7K in Q4 2020. 88 funds tracked by Wall St. Rank hold OVID as of Q1 2021.

  • Leonteq Securities AG reported no remaining Ovid Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Leonteq Securities AG sold 12,000 Ovid Therapeutics shares in Q1 2021, an estimated $27.7K.
  • Leonteq Securities AG first reported a position in Ovid Therapeutics in Q4 2020 and held it in 1 quarter.
  • Leonteq Securities AG's Ovid Therapeutics position peaked at $27.7K in Q4 2020.
  • 88 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2021.

Based on Leonteq Securities AG's 13F filing for Q1 2021, filed 26 Mar 2026.